DHCare Signs Definitive Agreement to Acquire Ottobock’s Human Mobility Division

The carve out and acquisition marks a significant step in  building a leading European provider of Mobility solutions 

London, United Kingdom – 19th June 2026 

DHCare, recently formed from the acquisition of Invacare Europe and DHG, has  signed a definitive agreement to carve out and acquire the Human Mobility  division of Ottobock, a globally recognised provider of complex power  wheelchairs and specialist mobility solutions. The planned acquisition would  represent DHCare’s first under its new ownership structure with Rhône, a global  private equity firm, and marks a defining step in building a truly comprehensive  Mobility platform that can serve all end users, clinicians, dealer partners, and  healthcare systems across Europe. 

The transaction, which remains subject to the satisfactory completion of  customary closing conditions expected to complete in H2 2026, would bring  together DHCare’s decades of clinical expertise and breadth of portfolio across  Mobility and Care Management, with Ottobock Human Mobility’s deep technical  heritage and strong presence in the DACH region, particularly in the provision of  complex power wheelchairs. 

The combination of DHCare and Ottobock Human Mobility would form one of  Europe’s most comprehensive offerings in the post-acute mobility segment, spanning Manual and Powered Wheelchairs, Power Add Ons, Complex  Rehabilitation Solutions, Pressure Ulcer Prevention, Safe Moving & Handling, and  Care Environment solutions. Customers, dealer partners, and end users across  Europe would benefit from access to an expanded portfolio underpinned by a  shared commitment to clinical outcomes, health economic evidence, and  product quality. 

Ottobock’s Human Mobility platform brings recognised strength in Complex  Power Wheelchair provision, an area of growing clinical and commercial  importance across European healthcare systems, as well as a significant presence  in the DACH region, complementing DHCare’s existing pan-European footprint  and creating a strong, more geographically balanced group. Together, the  combined entity will be well positioned to support customers and end users  across both the continuum of care and individual mobility needs – from everyday mobility requirements through to the most complex clinical cases.

Graham Ewart, CEO of DHCare, said: “This acquisition marks an important  milestone for DHCare. It’s our first under new ownership, our first as a combined  platform, and one that sets a clear direction of travel for this business. By bringing  Ottobock Human Mobility into DHCare, we are taking a meaningful step towards  our ambition of not only being a leading European provider of mobility solutions,  but doing so by supporting our clinicians, dealer partners, and end users with  high quality, clinically proven solutions, and best-in-class technical support and  after-sales service.” 

“The complementary strengths of both organisations, in product, geography, and  clinical expertise, will allow DHCare to support our valued customers, dealer  partners, and end users in more ways, and to a significantly higher standard and  benefit, than either business could achieve alone.” Continued Patrick Mundt,  Managing Director at Rhône. 

Oliver Jacobi, CEO of Ottobock, said: “By selling our wheelchair business, we are  sharpening our strategic focus on our core business. At the same time, with  DHCare we have found the right investor for Human Mobility. The team has built  a technologically leading business with strong clinical credibility and close  customer relationships. We are convinced that Human Mobility has the best  opportunities for growth in its new environment.” 

The completion of the proposed transaction is subject to customary consultation  processes, approvals, and closing conditions. Financial terms have not been  disclosed. 

In connection with this transaction, the French subsidiaries of both groups have  entered into exclusive negotiations for the sale of the French Human Mobility  business, and the relevant employee information and consultation processes will  be initiated shortly. 

About DHCare 

DHCare is a global medical device company that supports efforts to move health  forward by delivering innovative and leading solutions for individuals whose lives  are impacted by reduced movement. 

We strive to constantly support our healthcare partners, and the people whose healthcare needs they serve, working to keep improving the vital connections between movement and health, enabling accelerated recovery and healthy independence in daily living.

Press Contact 

Global Communications Team 

4D/E, The Ark,  

201 Talgarth Road,  

Hammersmith,  

London, W6 8BJ, UK 

globalcomms@dhcare.com 

www.dhcare.com 

About Rhone 

Rhône, established in 1996, is a global private equity firm with a focus on  investments in businesses with an international presence. Rhône’s investment  philosophy includes the development of strong, strategic partnerships with the  companies in which it invests. Rhône has a history of successful corporate carve out transactions and working with entrepreneur and family-led businesses, and  operates across its London, New York, Madrid, and Milan offices. Rhône has  invested in a diversified portfolio of companies including investments in the  consumer and industrial sectors. For more information about Rhône, its  investment professionals, and its current portfolio, please visit  www.rhonegroup.com. 

Press Contact 

Brunswick Group 

RHONE@brunswickgroup.com 

About Ottobock 

Ottobock, a listed global MedTech champion, combines over 100 years of  tradition with outstanding innovative strength in the fields of prosthetics, neuro orthotics and exoskeletons. Ottobock develops innovative fitting solutions for  people with limited mobility and is driving the digitalization of the industry.  Founded in Berlin in 1919, the company has business activities in 45 countries  with nearly 9,300 employees (FTEs) worldwide and operates the largest  international patient care network with around 420 patient care clinics. Ottobock  is shaping the future of human bionics with a strong R&D ratio in the products  and components business and over 2,600 patents and patent applications.  Ottobock’s mission of improving freedom of movement, quality of life and  independence is deeply rooted in the company’s DNA, as is its social  commitment: Ottobock has been a partner and supporter of the Paralympics  since 1988.